NOHA: A Promising Biomarker for Determining Estrogen Receptor Status Among Patients With Breast Cancer in Resource-Constrained Settings
Open Access
- 1 December 2022
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 8 (8) , e2200192
Abstract
PURPOSE: Challenges to breast cancer control in low-and middle-income countries exist because of constrained access to care, including pathology services. Immunohistochemistry (IHC)–based estrogen receptor (ER) analysis is limited-nonexistent because of few and inadequately staffed and equipped pathology laboratories. We have identified Nw-hydroxy-L-Arginine (NOHA) as a blood-based biomarker to distinguish ER status in US patients with breast cancer. Here, we examine NOHA's clinical utility as an ER IHC alternative in Tanzanian patients. MATERIALS AND METHODS: Following informed consent, 70 newly diagnosed, known or suspected patients with breast cancer were enrolled at Kilimanjaro Christian Medical Center; basic, deidentified clinical and sociodemographic data were collected. For each, a needle prick amount of blood was collected on a Noviplex plasma card and stored at −80°C. Plasma cards and unstained tumor pathology slides were shipped regularly to US laboratories for NOHA, histologic and IHC analysis. NOHA and IHC assay operators were blinded to each other's result and patient clinical status. Paired NOHA and IHC results were compared. RESULTS: Slides from 43 participants were available for pathological analysis in the United States. Of those with confirmed malignancy (n = 39), 44%, 51%, 5% were ER-positive, ER-negative, and ER inconclusive, respectively. NOHA levels were available among 33 of 43 of those with pathological data and showed distinct threshold levels correlating 100% to tumor ER IHC and disease categorization where a level below 4 nM, from 4 to 8 nM, and above 8 nM signified ER-negative, ER-positive, and no cancer, respectively. CONCLUSION: The results are consistent with findings from US patients and suggest NOHA's clinical utility as an accessible IHC replacement in determining ER status among low-and middle-income country patients with breast cancer, promising to extend access to cost-efficient, available hormonal agents and improve outcomes.Keywords
This publication has 17 references indexed in Scilit:
- Oncologic Care and Pathology Resources in Africa: Survey and RecommendationsJournal of Clinical Oncology, 2016
- International Variation in Female Breast Cancer Incidence and Mortality RatesCancer Epidemiology, Biomarkers & Prevention, 2015
- Receptor-Defined Subtypes of Breast Cancer in Indigenous Populations in Africa: A Systematic Review and Meta-AnalysisPLOS Medicine, 2014
- Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case seriesBreast Cancer Research, 2013
- Molecular Profiling for Breast Cancer: A Comprehensive ReviewBiomarkers in Cancer, 2013
- NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in OncologyJournal of the National Comprehensive Cancer Network, 2011
- Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's boxBMC Medicine, 2011
- Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010The Lancet Oncology, 2011
- Clinical and Epidemiologic Profile of Breast Cancer in TanzaniaBreast Disease, 2010
- Breast Cancer in Limited-Resource Countries: Diagnosis and PathologyThe Breast Journal, 2006